Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41
about
The C terminus of the B5 receptor for herpes simplex virus contains a functional region important for infection.Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusionStructural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis.Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potencyThe M-T Hook Structure Is Critical for Design of HIV-1 Fusion InhibitorsDiscovery of Critical Residues for Viral Entry and Inhibition through Structural Insight of HIV-1 Fusion Inhibitor CP621-652Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide regionRole of the simian virus 5 fusion protein N-terminal coiled-coil domain in folding and promotion of membrane fusion.Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitorStructure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41.Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41Mutational analysis of the putative fusion domain of Ebola virus glycoprotein.Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoproteinAmino acid residues in the cytoplasmic domain of the Mason-Pfizer monkey virus glycoprotein critical for its incorporation into virions.Activity of the Mason-Pfizer monkey virus fusion protein is modulated by single amino acids in the cytoplasmic tail.A conserved trimerization motif controls the topology of short coiled coils.Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state.Rapid progression to simian AIDS can be accompanied by selection of CD4-independent gp120 variants with impaired ability to bind CD4.Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1.The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entryConvergent evolution of ribonuclease h in LTR retrotransposons and retroviruses.Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sitesTargeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.Variable sensitivity to substitutions in the N-terminal heptad repeat of Mason-Pfizer monkey virus transmembrane protein.Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer.Selection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HSpring-loaded heptad repeat residues regulate the expression and activation of paramyxovirus fusion protein.Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue.Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs.N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.Complementation of diverse HIV-1 Env defects through cooperative subunit interactions: a general property of the functional trimer.Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm.Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41.HIV envelope: challenges and opportunities for development of entry inhibitors.Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.Functional importance of the coiled-coil of the Ebola virus glycoprotein.Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition.Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
P2860
Q24529146-6C31C1A3-54BE-4D76-9084-174040C94D00Q27619600-0E26EF02-85FB-4545-83B2-44E288E68A7DQ27635422-87E44D69-22C5-4106-9E9F-1BAD716391B7Q27650133-3F864BF1-5450-42A8-B585-238B5D74BA2BQ27671434-62555320-8610-4B74-815E-A58C84D256DCQ27678581-32C224A8-A472-463E-902B-2005A1AE711AQ28360391-6E75F4F0-AEE2-4259-827A-438B04EC3C58Q33717024-3CE4EC2C-22DA-4007-ABF6-51FF6E1E28C4Q33724295-83430121-4E9E-4D6F-ADDA-D4F5DC775AA0Q33780643-B6A9BFA3-745A-4193-ADEB-15A8525039A2Q33787186-84C045BC-C4FB-49FF-8E02-14016EAF819CQ33807129-80F2C16A-9FCC-4F21-9970-AE031B7E64E3Q33821928-3CB529BD-F0E3-4A5B-B195-16BD3F3A0C85Q33854904-0047FD97-120A-43F1-AE26-AF1354211964Q33987373-788184EF-C9E0-47DB-A991-864B7B4B1ADEQ33987377-6BF055D0-B102-44E9-B3D9-C06C457C3351Q34047976-D9BA04EA-09B0-406A-AB56-2025BD1B1034Q34342264-E2DDB523-9844-46A8-9EB4-2AA1E026A6FBQ34342950-7E4E41B6-F850-495B-AD5D-CA1972D6420AQ34361680-78857751-C89D-4745-BBC5-CB83C7558A86Q34412839-112A10FD-1C5F-477A-8622-D351C6490DE0Q34458880-ABFF1EBE-A642-4823-A968-F1465828DFADQ34466260-4AA4D399-7DFC-4AD9-9FF6-9A7DD5D3000FQ34981730-C695FF3F-800F-40CD-9133-36C7C71FDD50Q35105124-C7154BBD-4251-4AA5-9A71-18DBE93B464AQ35596474-9F8205AB-B1BC-4C59-9B72-13F5EA54298BQ35599288-39A6B0F0-7135-4366-80A2-EFDEA4524609Q35785110-632AF50C-2D79-41BC-93F7-E56A802EA55BQ35857279-134B3CCD-F197-48A8-B426-E962E7419E90Q36267348-0FA82AA1-81FC-4B74-93E1-2482D7B24665Q36565090-E4645954-06F3-44D8-9707-286FED85FC95Q36954635-8E13D42C-A0B4-4B53-B8A4-5F61FC1427A0Q37334851-892D32B8-DEDC-4803-B5E6-A053BFCA1E5CQ37348882-12A13973-C5D4-433B-80E5-2BA5D857606CQ37422890-8BEDE6C3-5363-4983-BB15-B2A0C35968EDQ37850183-B71283FA-D4F4-44F0-8B92-8E12C3262211Q39455561-0D7451DF-703B-4476-B9BE-BE6E728152E9Q39539619-2DDB57E0-7419-45B6-9891-90B3E2C77663Q39943795-31E97EAF-4502-4168-88B6-BA6590AD2297Q40141950-0E891D86-9510-4367-A3BA-8818F45403DD
P2860
Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Mutational analysis of residue ...... e 1 transmembrane protein gp41
@ast
Mutational analysis of residue ...... e 1 transmembrane protein gp41
@en
type
label
Mutational analysis of residue ...... e 1 transmembrane protein gp41
@ast
Mutational analysis of residue ...... e 1 transmembrane protein gp41
@en
prefLabel
Mutational analysis of residue ...... e 1 transmembrane protein gp41
@ast
Mutational analysis of residue ...... e 1 transmembrane protein gp41
@en
P2860
P1433
P1476
Mutational analysis of residue ...... e 1 transmembrane protein gp41
@en
P2860
P304
P577
1998-12-01T00:00:00Z